Exploring translation and commercialisation barriers of microbiome research and innovation

Introduction 

LYVA Labs has been funded by iiCON (Infection Innovation Consortium) via UKRI, to run a project exploring commercialisation opportunities and barriers relating to human and animal microbiome products. 

This project builds on insights from a Microbials Accelerator programme LYVA Labs delivered on behalf of Innovate UK. 24 UK founders benefitted from the programme, delivered alongside world-leading microbials academic expertise, to provide the commercialisation support needed to help accelerate their business growth.   

The overall aim is to identify how businesses can be better supported to develop and commercialise microbiome products more quickly.

LYVA Labs will create a microbiome innovation network focused on improving pathways towards clinical and commercial impact by convening researchers, industry, healthcare bodies, and business developers to identify solutions to microbiome research translation challenges.   

The Ask 

To support this work, you are kindly requested to spend 10 minutes completing this short survey to help us better understand some of the barriers relating to microbiome research commercialisation.   

This will supplement those barriers identified in the Microbiome Strategic Roadmap and via consultation with stakeholders such: as clinical trial design, regulatory hurdles, data analytics and modelling, manufacturing, and formulation.   

Our aim is to engage academics, healthcare providers, regulators, industry and their supply chains, and others to better understand these barriers, and how to address them, including convening a series of workshops in Spring 2025. The insights from this survey will inform the workshop design, development of the microbiome innovation network and to influence policy.

Fill in the survey here